Published in Mol Pharm on September 10, 2013
Effects of Gastric pH on the Pharmacokinetics of Dasatinib | NCT01398046
Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology (1997) 3.16
pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest (1975) 3.07
Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharmacol Ther (2012) 2.38
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol (1998) 1.90
Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med (1991) 1.40
Phase I study of the effect of gastric acid pH modulators on the bioavailability of oral dasatinib in healthy subjects. J Clin Pharmacol (2009) 1.11
Modification of gastric pH with oral glutamic acid hydrochloride. Clin Pharm (1991) 1.10
Ad libitum choline intake in healthy individuals meets or exceeds the proposed adequate intake level. J Nutr (2005) 1.10
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother (1995) 1.04
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm (2013) 1.00
Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol (2010) 0.98
Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol (1998) 0.95
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol (2010) 0.92
pH dependence of organic anion-transporting polypeptide 2B1 in Caco-2 cells: potential role in antiretroviral drug oral bioavailability and drug-drug interactions. J Pharmacol Exp Ther (2010) 0.90
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res (2005) 4.13
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Estimation of the net acid load of the diet of ancestral preagricultural Homo sapiens and their hominid ancestors. Am J Clin Nutr (2002) 1.98
Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev (2007) 1.91
Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J Pharmacol Exp Ther (2005) 1.67
Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther (2002) 1.64
A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother (2008) 1.58
Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation (2003) 1.54
Effects of renal failure on drug transport and metabolism. Pharmacol Ther (2005) 1.53
The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors. Anesth Analg (2002) 1.51
The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res (2009) 1.46
Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J (2009) 1.43
Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet (2002) 1.41
Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade. Transplantation (2010) 1.23
Biochemical mechanisms of cyclosporine neurotoxicity. Mol Interv (2004) 1.19
Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin Ther (2010) 1.15
Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm (2006) 1.14
The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res (2008) 1.12
Relationship and interaction between sodium and potassium. J Am Coll Nutr (2006) 1.12
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol (2006) 1.10
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr (2009) 1.10
Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation (2005) 1.10
Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. Pharmacotherapy (2011) 1.09
A guide to rational dosing of monoclonal antibodies. Clin Pharmacokinet (2012) 1.08
Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos (2006) 1.08
Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Infect Dev Ctries (2008) 1.06
Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther (2002) 1.04
Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res (2008) 1.03
Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenet Genomics (2008) 1.03
Effects of drug transporters on volume of distribution. AAPS J (2009) 1.01
Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos (2004) 1.01
Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm (2013) 1.00
Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci (2002) 1.00
In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab Dispos (2006) 1.00
Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos (2004) 0.99
CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J Pharmacol Exp Ther (2003) 0.99
Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet (2003) 0.97
Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and gg918. Drug Metab Dispos (2003) 0.97
P-glycoprotein (P-gp/MDR1)-mediated efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res (2004) 0.96
Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J Pharmacol Exp Ther (2006) 0.95
Liver and kidney transplantation in HIV-infected patients. AIDS Rev (2009) 0.95
Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin Cancer Res (2012) 0.95
Diet-induced acidosis: is it real and clinically relevant? Br J Nutr (2009) 0.94
Can the enhanced renal clearance of antibiotics in cystic fibrosis patients be explained by P-glycoprotein transport? Pharm Res (2002) 0.93
Alterations in glucose metabolism by cyclosporine in rat brain slices link to oxidative stress: interactions with mTOR inhibitors. Br J Pharmacol (2004) 0.93
Solid organ transplantation: referral, management, and outcomes in HIV-infected patients. AIDS Read (2006) 0.93
In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J Pharmacol Exp Ther (2003) 0.93
Light-activated regulation of cofilin dynamics using a photocaged hydrogen peroxide generator. J Am Chem Soc (2010) 0.93
Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice. Pharm Res (2013) 0.92
Expression and function of ABCB1 and ABCG2 in human placental tissue. Drug Metab Dispos (2005) 0.92
Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev (2011) 0.92
Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos (2006) 0.91
Intestinal drug transporters: an overview. Adv Drug Deliv Rev (2012) 0.91
A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer. Biopharm Drug Dispos (2013) 0.91
Renal net acid excretion capacity is comparable in prepubescence, adolescence, and young adulthood but falls with aging. J Am Geriatr Soc (2008) 0.91
Covalent binding of the nitroso metabolite of sulfamethoxazole is important in induction of drug-specific T-cell responses in vivo. Mol Pharmacol (2008) 0.91
Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther (2003) 0.90
BDDCS class prediction for new molecular entities. Mol Pharm (2012) 0.89
Estimates of daily net endogenous acid production in the elderly UK population: analysis of the National Diet and Nutrition Survey (NDNS) of British adults aged 65 years and over. Br J Nutr (2008) 0.88
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol (2005) 0.88
Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients. Transplantation (2014) 0.87
Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci (2011) 0.87
Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther (2002) 0.87
Studies on the chemical reactivity of 2-phenylpropionic acid 1-O-acyl glucuronide and S-acyl-CoA thioester metabolites. Chem Res Toxicol (2002) 0.86
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects. Br J Clin Pharmacol (2012) 0.86
Assessment and validation of the MS/MS fragmentation patterns of the macrolide immunosuppressant everolimus. J Mass Spectrom (2007) 0.86
Comparison of furosemide and vinblastine secretion from cell lines overexpressing multidrug resistance protein (P-glycoprotein) and multidrug resistance-associated proteins (MRP1 and MRP2). Pharmacology (2002) 0.85
Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit (2004) 0.85
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicol Sci (2012) 0.85
The evolution-informed optimal dietary potassium intake of human beings greatly exceeds current and recommended intakes. Semin Nephrol (2006) 0.85
Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers. J Pharm Sci (2009) 0.84
Mechanistic studies on the bioactivation of diclofenac: identification of diclofenac-S-acyl-glutathione in vitro in incubations with rat and human hepatocytes. Chem Res Toxicol (2003) 0.84
Lead PK commentary: predicting human pharmacokinetics. J Pharm Sci (2011) 0.84
Spatial heterogeneity in the response of the proximal femur to two lower-body resistance exercise regimens. J Bone Miner Res (2014) 0.84
Management of osteoporosis in CKD Stages 3 to 5. Am J Kidney Dis (2010) 0.83
Is Ciprofloxacin a Substrate of P-glycoprotein? Arch Drug Inf (2011) 0.83
Predicting when biliary excretion of parent drug is a major route of elimination in humans. AAPS J (2014) 0.83
Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med (2002) 0.83
Comparison of the effects of cyclosporin a on the metabolism of perfused rat brain slices during normoxia and hypoxia. J Cereb Blood Flow Metab (2002) 0.82
Effects of short-term alendronate on bone mineral density in haemodialysis patients. Nephrology (Carlton) (2005) 0.82
Identification, expression, and functional characterization of full-length and splice variants of murine organic anion transporting polypeptide 1b2. Mol Pharm (2009) 0.82
Studies on the reactivity of clofibryl-S-acyl-CoA thioester with glutathione in vitro. Drug Metab Dispos (2002) 0.81
Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transporters. Pharm Res (2002) 0.81
Distinguishing between the permeability relationships with absorption and metabolism to improve BCS and BDDCS predictions in early drug discovery. Mol Pharm (2014) 0.81
Studies on the chemical reactivity of diclofenac acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab Dispos (2003) 0.80
Modulation of cell adhesion molecules in various epithelial cell lines after treatment with PP2. Mol Pharm (2005) 0.80
Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. Hepatology (2011) 0.80
Membrane transporters in drug discovery and development: A new mechanistic ADME era. Mol Pharm (2006) 0.79
Pharmacokinetic differences corroborate observed low tacrolimus dosage in Native American renal transplant patients. Drug Metab Dispos (2011) 0.79
pH Dependent but not P-gp Dependent Bidirectional Transport Study of S-propranolol: The Importance of Passive Diffusion. Pharm Res (2015) 0.79
Metabolic acidosis and progression of chronic kidney disease. J Am Soc Nephrol (2009) 0.79
The nonenzymatic reactivity of the acyl-linked metabolites of mefenamic acid toward amino and thiol functional group bionucleophiles. Drug Metab Dispos (2013) 0.79